EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antimicrobial susceptibility and treatment of clinical cases of yersiniosis in Aotearoa | New Zealand

Lucia Rivas iD, Jenny Szeto, Juliet Elvy, Kristin Dyet, Jackie Wright, Ernest Williams, Brent Gilpin iD

Microbiology Spectrum · 2025

DOI: 10.1128/spectrum.02751-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Lucia Rivas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Environmental Science and Research (ESR), Christchurch Science Centre, Christchurch, Canterbury, New Zealand. Hauptthemen laut MEDLINE: Yersinia Infections, Anti-Bacterial Agents, Yersinia, Yersinia enterocolitica. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Research Council of New Zealand, Ministry for Business Innovation and Employment.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Yersiniosis is the second most notified bacterial disease in Aotearoa | New Zealand (NZ). National clinical treatment guidelines for yersiniosis are available, but there is a lack of supporting antimicrobial susceptibility data for clinical isolates of Yersinia spp. and prescribing data for yersiniosis cases. Data were collected through interviews with 148 consenting individuals notified with yersiniosis. Forty-three percent ( n = 63) of cases indicated antimicrobial use while symptomatic with yersiniosis, including two cases with dual diagnosis (Campylobacteriosis). Children under the age of 5 were predominantly notified with Yersinia enterocolitica (YE) biotype (BT) 2/3 (87%; 27/31) and reported significantly ( P = 0.008) less antimicrobial use compared to adults (aged 20–70+ years). Antimicrobial use was significantly ( P = 0.006) higher for cases reporting pre-existing gastrointestinal condition(s) and with YE BT 1A (26%; 12/47) compared to YE BT 2/3 (8%; 7/86). Eighty-six percent (44/51) of cases that indicated antimicrobial use identified the commencement date. Of these, 9% (4/44), 77% (34/44), and 14% (6/44) received an antimicrobial(s) as either empirical, directed, or empirical and directed treatment, respectively. Trimethoprim-sulfamethoxazole (49% [25/51]), ciprofloxacin (16% [8/51]), and doxycycline (10% [5/51]) were the most prescribed antimicrobials. Phenotypic antimicrobial susceptibility testing demonstrated clinical Yersinia spp. were susceptible to all antimicrobials commonly prescribed for the treatment of yersiniosis. Whole-genome sequence (WGS) analysis showed very few ( 1 – 3 ) antimicrobial resistance (AMR) genes within the Yersinia genomes. The results support the current antimicrobial prescribing recommendation for the treatment of yersiniosis in NZ and the utility of WGS to assess for AMR profiles in Yersinia spp. IMPORTANCE This study demonstrates that currently almost half of yersiniosis cases interviewed receive antimicrobial treatment, with most prescriptions as directed therapy after a diagnosis has been made. This study also confirms the appropriateness of current treatment guidelines for the management of yersiniosis in NZ, and that most primary care practitioners in the study areas follow these recommendations. Phenotypic testing was well correlated with the genomic assessments of antimicrobial resistance (AMR). Both types of analysis indicated a low level of AMR for Yersinia spp. in New Zealand (NZ) compared to data from overseas studies. However, ongoing surveillance given the burden of yersiniosis and high rates of treatment in NZ is paramount to ensuring timely detection of emerging multi-drug resistance and to help devise evidence-informed interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Yersinia InfectionsAnti-Bacterial AgentsYersiniaYersinia enterocoliticaHumansNew ZealandAdultMiddle AgedChild, PreschoolMaleFemaleMicrobial Sensitivity TestsChildAgedYoung AdultAdolescentInfantAged, 80 and over

Stichwörter der Autor:innen

Yersiniaantibiotic resistancegastrointestinal infectionyersiniosis

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Institute of Environmental Science and Research (ESR), Christchurch Science Centre, Christchurch, Canterbury, New Zealand.
  • Institute of Environmental Science and Research, Kenepuru Science Centre, Porirua, Wellington, New Zealand.
  • Awanui Labs, Dunedin Hospital, Dunedin, Otago, New Zealand.
  • Institute of Environmental Science and Research, Wallaceville Science Centre, Upper Hutt, Wellington, New Zealand.

ORCID-Profile: Lucia Rivas, Brent Gilpin

Förderung

  • Health Research Council of New Zealand
  • Ministry for Business Innovation and Employment

Zitieren

APA

Rivas, L., Szeto, J., Elvy, J., Dyet, K., Wright, J., Williams, E., & Gilpin, B. (2025). Antimicrobial susceptibility and treatment of clinical cases of yersiniosis in Aotearoa | New Zealand. Microbiology Spectrum. https://doi.org/10.1128/spectrum.02751-24

Vancouver

Rivas L, Szeto J, Elvy J, Dyet K, Wright J, Williams E, et al. Antimicrobial susceptibility and treatment of clinical cases of yersiniosis in Aotearoa | New Zealand. Microbiology Spectrum. 2025. doi:10.1128/spectrum.02751-24

BibTeX
@article{Rivas2025,
  author = {Rivas, Lucia and Szeto, Jenny and Elvy, Juliet and Dyet, Kristin and Wright, Jackie and Williams, Ernest and Gilpin, Brent},
  title = {Antimicrobial susceptibility and treatment of clinical cases of yersiniosis in Aotearoa | New Zealand},
  journal = {Microbiology Spectrum},
  year = {2025},
  doi = {10.1128/spectrum.02751-24}
}
Kostenlos starten →